[TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].
Ayrault
Olivier
O
Zindy
Frédérique
F
Roussel
Martine F
MF
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018797:Cell Cycle Proteins; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D016922:Cellular Senescence / Q000235:genetics; D056741:Cyclin D; D018844:Cyclin-Dependent Kinases / Q000502:physiology; D016213:Cyclins / Q000502:physiology; D004249:DNA Damage; D005134:Eye Neoplasms / Q000188:drug therapy / Q000235:genetics*; D016161:Genes, Retinoblastoma; D019942:Genes, p16; D016158:Genes, p53; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D008954:Models, Biological; D009687:Nuclear Proteins / Q000502:physiology; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000502:physiology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors / Q000502:physiology; D012175:Retinoblastoma / Q000188:drug therapy / Q000235:genetics*; D016160:Retinoblastoma Protein / Q000502:physiology*; D019772:Topotecan / Q000008:administration & dosage; D025803:Tumor Suppressor Protein p14ARF / Q000502:physiology; D016159:Tumor Suppressor Protein p53 / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
D018797:Cell Cycle Proteins; D056741:Cyclin D; D016213:Cyclins; D007093:Imidazoles; C482775:MDM4 protein, human; D009687:Nuclear Proteins; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D016160:Retinoblastoma Protein; D025803:Tumor Suppressor Protein p14ARF; D016159:Tumor Suppressor Protein p53; C482205:nutlin 3; D019772:Topotecan; C497206:MDM2 protein, human; C497207:Mdm2 protein, mouse; D051736:Proto-Oncogene Proteins c-mdm2; D018844:Cyclin-Dependent Kinases